In June 2015, 60 researchers from 11 countries assembled at the Monash University Prato Centre near Florence, Italy, for an international conference-Collaborative Clinical Trials in Anaesthesia. This was the third conference since 2012, aiming to promote international collaboration among researchers in multicentre trials. It is a global initiative of Monash University and the Department of Anaesthesia and Perioperative Medicine, Alfred Hospital, and was led by the Director, Paul Myles, and Jamie Cooper, Director of the Australian and New Zealand Intensive Care Research Centre, at Monash University, Melbourne, Australia.
During the four-day conference 19 trials were presented for discussion. Seven were funded by Australia's National Health and Medical Research Council (NHMRC) to a total of more than AUD$11 million. The success of the conference reflects outstanding leadership of Australasian University multidisciplinary anaesthesia led research groups in promoting strong collaborative partnerships to ensure continuing international support for major projects of the highest quality that provide reliable and valid evidence of the worth or harm of old and new drugs and technologies.
The primary goal of this paper is to demonstrate the link between the completion and publication of the MASTER trial to the formation of the Australian and New Zealand College of Anaesthetists (ANZCA) Clinical Trials Network (CTN) and the current leadership of Australasian investigators in multidisciplinary international collaboration in anaesthesia and perioperative medicine. The MASTER Trial idea began to emerge, over 30 years ago, at several continuing education meetings in the Department of Anaesthesia at St Vincent's Hospital, Melbourne, with presentations and discussions of the merits of local anaesthetic blocks. There was a belief among anaesthetists and general and vascular surgeons, at these meetings, that such blocks improved surgical outcome. However, at that time, there was little quality research evidence to support such views. In 1987 a small, single centre RCT reported superior outcomes in patients assigned to epidural block 1 . This study and an accompanying editorial set the stage for the development of the MASTER Trial 2-4 . In 1993, Davies et al published another small, single centre RCT of epidural block in general surgery, which demonstrated no difference between treatment groups 5 . Davies subsequently acknowledged (personal communication) that this study lacked adequate statistical power so that the negative trial result was possibly due to a Type II error, the high probability of not detecting a true difference between treatment groups 6 .
However, there were earlier experiences which drove my pursuit of the MASTER Trial idea. First, at the Melbourne Royal Women's Hospital (RWH) in 1969, I was influenced by Kevin McCaul, Director of Anaesthesia between 1951 and 1979. He led the transformation of labour ward analgesia using lumbar epidural and caudal blocks. However, I was also impressed by epidural block used for major cancer surgery. There were many kindred spirits in anaesthesia and gynaecology at that time; in particular, gynaecology registrar, Tony McCartney. These experiences in 1969 led directly to our partnership as anaesthetist and surgeon in two Perth hospitals between 1983 and 2005. Epidural block during and after surgery was always used for major cancer surgery.
Another important experience occurred in 1968, when I was an anaesthetic registrar at Prince Henry's Hospital, Melbourne. Blair Ritchie, then Senior Lecturer, Department of Medicine, Monash University, invited me to work in his respiratory laboratory. We studied the ventilatory response to carbon dioxide under conditions of respiratory muscle weakness induced with muscle relaxants; experiments inspired by the then common problem of re-establishing adequate spontaneous ventilation after surgery with relaxant general anaesthesia. The results of these experiments were published in 1970 7 I first met Konrad Jamrozik, an Oxford University trained clinical epidemiologist and Professor of Public Health at the University of Western Australia, in Perth, in 1989, and introduced him to the concept of a multicentre RCT to test the effect of epidural block on outcome after surgery. After detailed discussion, he committed to the team, consisting then of me, Jamrozik, Davies and another anaesthetist at St Vincents, Brendan Silbert. In 1991, Davies realised that because of his administrative commitments to St Vincent's, and ANZCA, he was unable to continue with the project and delegated full responsibility to Silbert. However, it is important to acknowledge Davies' strong and continuous support for the project.
From June to September 1990, I spent three months as Visiting Professor, Bowman Gray Medical School, Wake Forest University, North Carolina. There, I wrote a paper describing the rationale and method for a large multicentre RCT 6 . I also wrote the first draft of what would become the NHMRC Grant. I sent these to David Glass, at Dartmouth Hitchcock Medical School, New Hampshire, senior author of the earlier RCT showing improvement in outcome associated with epidural block 1 and to Sackett at McMaster. In August 1990, I visited Glass and Sackett and they encouraged me to commit to establishing a multicentre RCT. In 1991, Sackett provided a thorough critique of the grant proposal, concluding "I think you have made a good case for the trial". With the support of these respected clinical scientists, Jamrozik and I strengthened our commitment to fund and complete the trial.
From 1991 to 1995, Jamrozik and I, supported by Silbert, and later Philip Peyton (Austin Hospital, Melbourne) and Paul Myles (Alfred Hospital, Melbourne) visited departments and spoke at meetings across Australia and New Zealand to generate support. In 1995 and 1996, seed funding was provided by Hoechst Pharmaceuticals and Mallinckrodt Medical and with grants from ANZCA and the Health Department of Western Australia, we were able to appoint Karen Collins, an intensive care trained nurse as trial coordinator, a position she filled with distinction until the trial was completed and the results presented in New Orleans, in October 2001. In 1992 and 1993, Wally Thompson and Vernon van Heerden, consultants in Intensive Care at Sir Charles Gairdner Hospital, Perth, worked closely with Jamrozik and me in important aspects of trial design. We reviewed and precisely described the risk factors defining criteria for high-risk patient eligibility for the trial. All morbidity outcomes, particularly for sepsis and the systemic inflammatory response syndrome (SIRS) were reviewed and defined.
Yeager et al were the first group to empirically define a set of criteria to identify high-risk patients and another set of criteria to define each important 'morbidity' outcome 1 . Jamrozik and I both knew this was important, not only for the MASTER Trial, but also for future studies of any intervention on the outcome of a particular surgical procedure. It was important for two reasons. First, criteria for 'high-risk' were essential for medical comorbid conditions that a majority of senior leaders in anaesthesia, surgery and intensive care medicine would agree were important possible causes of post-surgical morbidity and could be precisely defined by laboratory tests and procedures specific to each medical complication. This was important for a multicentre study to enhance uniformity of criteria and definitions across a large number of sites. Secondly, the same principles applied for defining outcomes. For each outcome, in respect of a single organ system (e.g. cardiac, respiratory, renal) or across many systems (such as sepsis or SIRS), a comprehensive set of unambiguous, quantitative criteria was essential to limit uncertainty with respect to the diagnosis of an adverse outcome and to enhance uniformity of diagnoses across multiple sites. This was why we approached Thompson for assistance and why he recruited van Heerden to spend many hours with us to obtain agreement on every detail with respect to both high-risk criteria for trial entry and morbidity outcome definitions. As a result, these MASTER Trial definitions became the 'gold standard' for future multicentre studies [8] [9] [10] [11] .
Randomisation began in 1995 and continued until enrolment ceased in 2001. In November 1996, the NHMRC awarded the group AUD$506,000 and in 1999, AUD$210,000, to complete the study. Twenty-five hospitals in six countries randomised patients; over 50% of patients were recruited in Victoria, Australia. Full details of the design and conduct of the trial are described elsewhere [3] [4] .
The MASTER Trial results were published in 2002 3 . The manuscript was accepted by the Lancet at first submission, testament to the importance of the hypothesis and the rigour of the design. Despite assembling a study cohort of high risk patients, overall mortality for 888 patients compared on an intention-to-treat basis was only 4.8%. However, this sample size was calculated for a statistical power of 0.8, for a high risk group, with 50% frequency of the combined endpoint (death or at least one major complication) in the control group and a 20% reduction of this endpoint, to 40% frequency, in the epidural group. The findings of 60.7% and 57.1% frequencies in these groups demonstrates that the MASTER trial was not underpowered 6 .
The subsequent success of Australasian anaesthetists in providing international leadership in collaborative research in multicentre RCTs was an important consequence of the MASTER Trial. The MASTER Trial group and Davies were pivotal in the decision of ANZCA to support the establishment of the ANZCA CTN. ANZCA is the only specialist medical college in the world to establish such a network in association with expert epidemiologists, statisticians and methodologists in a nearby university. ANZCA Fellows should be justifiably proud of the College's vision and commitment to this important leadership role in research in anaesthesia and perioperative and pain medicine. With the recent success of Fellows in the 2015 round of NHMRC grants, in seven more projects, over AUD$30 million in NHMRC funds has been awarded to teams led by or involving ANZCA Fellows and other anaesthetists, since 2002. The future of anaesthesia outcomes research in Australia and New Zealand is assured by the ongoing very successful Strategic Research Workshops conducted by ANZCA and the CTN. I proudly support recent conclusions that high quality research in anaesthesia our region is, currently stronger and more diverse than in comparable nations in Europe and North America [12] [13] [14] [15] [16] .
